Propel Bio Management, LLC — 13F Holdings & Portfolio
CIK 1969764 · latest 13F-HR filed 2026-11-13
Propel Bio Management, LLC manages $188.6M in 13F-reported U.S. long-equity assets across 30 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are PAGP (17.47%), QUIT (16.57%), DCTH (5.12%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 5 new positions and exited 4; 7 existing positions rose in reported value and 18 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-11-13
vs 2026-06-30
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q3 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q2 26 → Q3 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
5 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 68.3%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 23, 2026.
SUITE 350
LOS ANGELES, CA 90025
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| HARDING, JAMES, FRANCIS Control | CHIEF COMPLIANCE OFFICER since Mar 2026 | Less than 5% | Individual |
| KAWAS, LEEN Control | MANAGING GENERAL PARTNER since Jan 2022 | 75% or more | Individual |
Ownership & leadership changes · 2 filings with changes since Oct 17, 2022
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedHua, Xue · CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since Mar 2024
- Listed againHARDING, JAMES, FRANCIS · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- No longer listedHARDING, JAMES, FRANCIS · CHIEF COMPLIANCE OFFICER · Less than 5% · listed since Sep 2022
- AddedHua, Xue · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ListedHARDING, JAMES, FRANCIS · CHIEF COMPLIANCE OFFICER · Less than 5%
- ListedKAWAS, LEEN · MANAGING GENERAL PARTNER · 75% or more · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- ACHIEVE LIFE SCIENCES INC$4.9M +18.7%
- MAZE THERAPEUTICS INC$3.9M +299.3%
- AQUESTIVE THERAPEUTICS INC$2.6M +43.5%
- PLAINS GP HOLDINGS LP$2.1M +6.7%
- CORVUS PHARMACEUTICALS INC$2.0M +189.6%
Top Trims
- PHATHOM PHARMACEUTICALS I-$3.3M -29.2%
- CORCEPT THERAPEUTICS INC-$3.2M -26.9%
- KYVERNA THERAPEUTICS INC-$3.1M -39.5%
- IMMUNIC INC-$2.8M -55.9%
- CELLDEX THERAPEUTICS INC-$2.6M -68.5%
New Positions
- COLLEGIUM PHARMACEUTICAL$9.0M
- CABALETTA BIO INC$3.9M
- PROKIDNEY CORP$3.3M
- OPUS GENETICS INC$1.3M
- SPYGLASS PHARMA INC$1.1M
Exited Positions
- ZEVRA THERAPEUTICS INC$3.6M
- EYEPOINT INC$2.7M
- SILENCE THERAPEUTICS PLC$2.1M
- SAGIMET BIOSCIENCES INC-A$973.0K
Propel Bio Management, LLC Holdings (2026-09-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PLAINS GP HOLDINGS LP | PAGP | 72651A207 | $33.0M | 17.47% | 1,272,360 | SH |
| 2 | ACHIEVE LIFE SCIENCES INC | QUIT | 004468500 | $31.3M | 16.57% | 3,864,148 | SH |
| 3 | DELCATH SYSTEMS INC | DCTH | 24661P807 | $9.7M | 5.12% | 604,664 | SH |
| 4 | COLLEGIUM PHARMACEUTICAL | COLL | 19459J104 | $9.0M | 4.75% | 410,175 | SH |
| 5 | CORCEPT THERAPEUTICS INC | CORT | 218352102 | $8.7M | 4.60% | 75,274 | SH |
| 6 | AQUESTIVE THERAPEUTICS INC | AQST | 03843E104 | $8.6M | 4.56% | 278,723 | SH |
| 7 | MILESTONE PHARMACEUTICALS | MIST | 59935V107 | $8.2M | 4.34% | 9,449,727 | SH |
| 8 | PHATHOM PHARMACEUTICALS I | PHAT | 71722W107 | $8.1M | 4.28% | 1,105,913 | SH |
| 9 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $6.8M | 3.62% | 549,186 | SH |
| 10 | ORCHESTRA BIOMED HOLDINGS | OBIO | 68572M106 | $5.6M | 2.96% | 896,701 | SH |
| 11 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $5.2M | 2.77% | 191,998 | SH |
| 12 | ABEONA THERAPEUTICS INC | ABEO | 00289Y206 | $5.0M | 2.66% | 956,007 | SH |
| 13 | ARTIVA BIOTHERAPEUTICS IN | ARTV | 04317A107 | $5.0M | 2.63% | 696,436 | SH |
| 14 | KYVERNA THERAPEUTICS INC | KYTX | 501976104 | $4.8M | 2.53% | 700,595 | SH |
| 15 | INVENTIVA SA - ADR | IVA | 46124U107 | $4.2M | 2.22% | 1,133,954 | SH |
| 16 | CABALETTA BIO INC | CABA | 12674W109 | $3.9M | 2.09% | 2,049,471 | SH |
| 17 | SAB BIOTHERAPEUTICS INC | SABS | 78397T202 | $3.8M | 2.00% | 1,187,422 | SH |
| 18 | PROKIDNEY CORP | PROK | 74291D104 | $3.3M | 1.77% | 2,009,733 | SH |
| 19 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $3.0M | 1.61% | 264,310 | SH |
| 20 | PALISADE BIO INC | PALI | 696389402 | $3.0M | 1.59% | 2,224,189 | SH |
| 21 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $2.7M | 1.46% | 357,966 | SH |
| 22 | SCYNEXIS INC | SCYX | 811292309 | $2.7M | 1.42% | 541,474 | SH |
| 23 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 35104E100 | $2.6M | 1.36% | 179,154 | SH |
| 24 | OVID THERAPEUTICS INC | OVID | 690469101 | $2.5M | 1.34% | 1,018,721 | SH |
| 25 | IMMUNIC INC | IMUX | 4525EP200 | $2.2M | 1.17% | 236,734 | SH |
| 26 | UPSTREAM BIO INC | UPB | 91678A107 | $1.8M | 0.94% | 335,389 | SH |
| 27 | OPUS GENETICS INC | IRD | 67577R102 | $1.3M | 0.69% | 270,036 | SH |
| 28 | CELLDEX THERAPEUTICS INC | CLDX | 15117B202 | $1.2M | 0.65% | 37,539 | SH |
| 29 | SPYGLASS PHARMA INC | SGP | 85220G109 | $1.1M | 0.57% | 41,418 | SH |
| 30 | LEONABIO INC | LONA | 04746L203 | $532.9K | 0.28% | 149,279 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-13 | $188.6M | 30 | 0001829126-26-012373 |
| 2026-06-30 | 2026-08-13 | $191.1M | 29 | 0001829126-26-008753 |
| 2026-03-31 | 2026-05-14 | $158.7M | 38 | 0000898432-26-000369 |
| 2025-12-31 | 2026-02-11 | $117.1M | 20 | 0000898432-26-000087 |
| 2025-09-30 | 2025-11-12 | $99.9M | 16 | 0000898432-25-000886 |
SUITE 350
LOS ANGELES, CA 90025